Stewart Lyman
Stewart Lyman is Owner and Manager of Lyman BioPharma Consulting LLC in Seattle. He provides advice to biotechnology and pharmaceutical companies as well as academic researchers and venture capital firms. Previously, he spent 14 years as a scientist at Immunex prior to its acquisition by Amgen.
-
Advances in the biomedical sciences are highly dependent upon researchers having a clear understanding of the current state of knowledge. This information is primarily acquired by having access to the scientific literature... Read more »
-
Are biotech and pharma companies doing well, or falling apart at the seams? People will have differences of opinion on this, but one thing is clear: it’s all relative.
At a speech to... Read more »
-
One or more notices of upcoming biopharma industry conferences arrive in my email every day. I give their agendas a quick glance before deleting them, as they’re seldom in areas I focus on. The... Read more »
-
Developing new medicines is an amazingly difficult undertaking. The research portion alone is daunting, and for those of us who have actually attempted it, humbling. A recent article reminded me just how... Read more »
-
If you bought a new toaster, carried it home, plugged it in, and it didn’t work, what would you do? Suppose you purchased a pineapple at the grocery store, sliced it open, and... Read more »
-
If you’ve been following the drug industry at all for the past few years, you know that Big Pharma has gone alliance crazy.
It seems that every other week a new deal is... Read more »
-
I frequently read comments from pundits and politicians decrying the US drug regulatory system, specifically the FDA. Many of these people, reading from the same PR playbook, will try to convince... Read more »
-
In the first part of this article, I detailed how pharma and biotech companies, along with the federal government, provide the majority of funding for biomedical research in the U.S. In... Read more »
-
In case you haven’t noticed, heart disease remains a debilitating illness for millions. Cancer, despite some recent advances, has not been cured. Drug resistant strains of bacteria are spreading across the globe.... Read more »
-
Biotechnology is a challenging business, with drug development timelines that are long, costly, and dependent on the approval of government regulatory agencies. The vast majority of biotechs never succeed in developing a new... Read more »
-
Cognitive dissonance is defined as “an uncomfortable feeling caused by holding conflicting ideas simultaneously.” I’m suffering from a serious case of discomfort as I try to figure out which is the bigger problem... Read more »
-
Doctors, patients, and investors who follow the biopharmaceutical business all recognize that the industry is exceedingly complex and in the midst of change. Companies struggle daily with a multifaceted mix of scientific,... Read more »
-
[Updated: 11:30 am, 11/4/10] The biotech industry was a key beneficiary last spring of the new health care law. $1 billion worth of Qualifying Therapeutic Discovery Project Credits were dangled... Read more »
-
I recently enjoyed reading two books on the mortgage meltdown, “The Big Short” by Michael Lewis and Gregory Zuckerman’s “The Greatest Trade Ever.” They each provided a detailed... Read more »
-
I agree with Carl Weissman’s recent Xconomy column about the ZymoGenetics acquisition when he says that Seattle needs to be a place where biotech startups thrive. Unfortunately, his column didn’t put forth... Read more »
-
The drug discovery and development process is a difficult one that takes considerable expertise in both the research and business realms. Seattle currently has approximately 103 biotechnology companies, 21 of which... Read more »
-
The rules regarding the Qualifying Therapeutic Discovery Project Credit have now been released by the Treasury Department. You can read the fact sheet, and detailed description of the legislation yourself,... Read more »
-
The biotech industry won a major victory last month when President Obama signed healthcare reform into law. Biologic drugs, those developed through genetic engineering techniques and incubated in living cells, will now... Read more »
-
Research is the lifeblood of the biotech and pharmaceuticals business. The pharma and biotech industry spent some $65 billion dollars on R & D in 2008, according to the Pharmaceutical Research and... Read more »
-
Well, 2009 did not turn out to be the biotechnology disaster here in Seattle that many people had predicted.
By my reckoning, only four of the local biotech companies that I track on... Read more »
